NASDAQ:CARA - Cara Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.26 -0.13 (-1.05 %)
(As of 05/20/2018 01:13 PM ET)
Previous Close$12.26
Today's Range$12.24 - $12.6199
52-Week Range$11.11 - $28.50
Volume392,227 shs
Average Volume484,557 shs
Market Capitalization$400.90 million
P/E Ratio-6.59
Dividend YieldN/A
Beta2.96

About Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics logoCara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700

Debt

Debt-to-Equity RatioN/A
Current Ratio11.47
Quick Ratio11.47

Price-To-Earnings

Trailing P/E Ratio-6.59
Forward P/E Ratio-5.68
P/E GrowthN/A

Sales & Book Value

Annual Sales$910,000.00
Price / Sales440.55
Cash FlowN/A
Price / CashN/A
Book Value$2.20 per share
Price / Book5.57

Profitability

EPS (Most Recent Fiscal Year)($1.86)
Net Income$-58,120,000.00
Net MarginsN/A
Return on Equity-57.40%
Return on Assets-52.21%

Miscellaneous

Employees37
Outstanding Shares32,700,000

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics (NASDAQ:CARA) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.04. View Cara Therapeutics' Earnings History.

What price target have analysts set for CARA?

12 brokers have issued 1-year price targets for Cara Therapeutics' shares. Their predictions range from $17.00 to $31.50. On average, they anticipate Cara Therapeutics' stock price to reach $25.1923 in the next twelve months. View Analyst Ratings for Cara Therapeutics.

What are Wall Street analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (3/21/2018)
  • 2. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)

Who are some of Cara Therapeutics' key competitors?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the folowing people:
  • Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 54)
  • Dr. Frédérique Menzaghi Ph.D., Sr. VP of R&D (Age 52)
  • Dr. Joseph Stauffer D.O., M.B.A., Chief Medical Officer (Age 52)
  • Dr. Michael E. Lewis Ph.D., Co-Founder and Chief Scientific Advisor (Age 66)
  • Dr. Mani Mohindru, Chief Financial Officer (Age 46)

Has Cara Therapeutics been receiving favorable news coverage?

Media coverage about CARA stock has trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cara Therapeutics earned a news sentiment score of 0.08 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.61%), Nexthera Capital LP (1.07%), ETF Managers Group LLC (1.03%), JPMorgan Chase & Co. (1.00%), C WorldWide Group Holding A S (0.71%) and UBS Group AG (0.55%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.

Which institutional investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Tiverton Asset Management LLC, C WorldWide Group Holding A S, JPMorgan Chase & Co. and Stifel Financial Corp. Company insiders that have sold Cara Therapeutics company stock in the last year include Dean Slagel, Derek T Chalmers and Frederique PhD Menzaghi. View Insider Buying and Selling for Cara Therapeutics.

Which institutional investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including Nexthera Capital LP, ETF Managers Group LLC, UBS Group AG, Wells Fargo & Company MN, LPL Financial LLC, DekaBank Deutsche Girozentrale, Commonwealth Equity Services LLC and Swiss National Bank. View Insider Buying and Selling for Cara Therapeutics.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $12.26.

How big of a company is Cara Therapeutics?

Cara Therapeutics has a market capitalization of $400.90 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-58,120,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Cara Therapeutics employs 37 workers across the globe.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.


MarketBeat Community Rating for Cara Therapeutics (CARA)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  426 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  619
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cara Therapeutics (NASDAQ:CARA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Cara Therapeutics in the last 12 months. Their average twelve-month price target is $25.1923, suggesting that the stock has a possible upside of 105.48%. The high price target for CARA is $31.50 and the low price target for CARA is $17.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.852.852.75
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.1923$25.4643$26.0357$26.1923
Price Target Upside: 105.48% upside106.69% upside111.67% upside116.47% upside

Cara Therapeutics (NASDAQ:CARA) Consensus Price Target History

Price Target History for Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics (NASDAQ:CARA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018HC WainwrightSet Price TargetBuy$22.00LowView Rating Details
3/16/2018Seaport Global SecuritiesReiterated RatingBuyLowView Rating Details
2/12/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$27.00 ➝ $21.00HighView Rating Details
1/3/2018Stifel NicolausReiterated RatingBuy$17.00HighView Rating Details
11/20/2017Canaccord GenuitySet Price TargetBuy$25.00N/AView Rating Details
11/7/2017Raymond JamesBoost Price TargetMarket Perform$25.00 ➝ $26.00N/AView Rating Details
11/7/2017CIBCLower Price Target$26.00 ➝ $24.00N/AView Rating Details
11/7/2017BMO Capital MarketsReiterated RatingMarket Perform$25.00N/AView Rating Details
10/17/2017ScotiabankBoost Price TargetOutperform$31.00 ➝ $31.50N/AView Rating Details
10/4/2017Needham & Company LLCReiterated RatingBuy$23.00LowView Rating Details
8/5/2017Piper JaffraySet Price TargetBuy$27.00HighView Rating Details
8/3/2017Royal Bank of CanadaLower Price TargetOutperform$31.00 ➝ $29.00LowView Rating Details
6/30/2017LaidlawLower Price TargetBuy$35.00 ➝ $30.00HighView Rating Details
5/19/2017Cantor FitzgeraldReiterated RatingOverweight$29.00LowView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Cara Therapeutics (NASDAQ:CARA) Earnings History and Estimates Chart

Earnings by Quarter for Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics (NASDAQ:CARA) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.53)($0.53)($0.53)
Q3 20181($0.49)($0.49)($0.49)
Q4 20181($0.58)($0.58)($0.58)

Cara Therapeutics (NASDAQ CARA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.4740)($0.5130)$0.19 millionViewN/AView Earnings Details
3/15/2018Q4 2017($0.39)($0.43)$0.11 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.35)($0.38)$0.27 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.61)($0.29)$0.13 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.81)$0.11 million$0.91 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.53)($0.81)ViewN/AView Earnings Details
11/3/2016Q3($0.47)($0.42)$0.09 millionViewN/AView Earnings Details
8/4/2016Q216($0.42)($0.48)$0.13 million$0.08 millionViewN/AView Earnings Details
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.25)$0.50 million$0.87 millionViewListenView Earnings Details
5/12/2015Q415($0.22)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details
3/26/2015Q4($0.28)($0.18)$1.00 million$0.91 millionViewListenView Earnings Details
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details
3/27/2014($0.18)($0.49)$0.90 million$0.97 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cara Therapeutics (NASDAQ:CARA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cara Therapeutics (NASDAQ CARA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 52.80%
Insider Trading History for Cara Therapeutics (NASDAQ:CARA)
Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics (NASDAQ CARA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Derek T ChalmersCEOSell5,400$15.00$81,000.001,071,392View SEC Filing  
2/15/2018Frederique Ph.D. MenzaghiSVPSell3,000$15.02$45,060.00119,000View SEC Filing  
1/24/2018Derek T ChalmersCEOSell12,500$15.00$187,500.001,073,792View SEC Filing  
1/24/2018Frederique Ph.D. MenzaghiSVPSell15,000$15.00$225,000.00122,000View SEC Filing  
11/1/2017Derek T ChalmersCEOSell16,000$12.66$202,560.001,066,292View SEC Filing  
7/14/2017Derek T ChalmersCEOSell25,000$15.05$376,250.001,107,292View SEC Filing  
7/14/2017Frederique Ph.D. MenzaghiVPSell3,000$15.00$45,000.00120,000View SEC Filing  
6/29/2017Dean SlagelDirectorSell250,000$25.87$6,467,500.00View SEC Filing  
3/31/2017Ventures Vi Lp RhoMajor ShareholderBuy500,000$18.19$9,095,000.00View SEC Filing  
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00123,000View SEC Filing  
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00129,000View SEC Filing  
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66314,988View SEC Filing  
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.001,087,292View SEC Filing  
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00141,000View SEC Filing  
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00147,000View SEC Filing  
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00153,000View SEC Filing  
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00159,000View SEC Filing  
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.0028,000View SEC Filing  
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cara Therapeutics (NASDAQ CARA) News Headlines

Source:
DateHeadline
Better Marijuana Stock: Insys Pharmaceuticals vs. Cara TherapeuticsBetter Marijuana Stock: Insys Pharmaceuticals vs. Cara Therapeutics
www.msn.com - May 19 at 3:03 PM
Forget Cara Therapeutics' Earnings -- Here's the Real NewsForget Cara Therapeutics' Earnings -- Here's the Real News
finance.yahoo.com - May 17 at 3:11 PM
Forget Cara Therapeutics Earnings -- Heres the Real NewsForget Cara Therapeutics' Earnings -- Here's the Real News
www.fool.com - May 17 at 1:40 PM
Global Marijuana Industry 2018 – Market Size, Analysis, Share, Research, Growth and ForecastGlobal Marijuana Industry 2018 – Market Size, Analysis, Share, Research, Growth and Forecast
www.marketwatch.com - May 17 at 5:40 AM
Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting 
finance.yahoo.com - May 15 at 5:20 AM
Edited Transcript of CARA earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of CARA earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 15 at 5:20 AM
Cara Therapeutics (CARA) Receives Consensus Recommendation of "Buy" from AnalystsCara Therapeutics (CARA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 14 at 5:37 AM
Research Analysts Set Expectations for Cara Therapeutics Q2 2018 Earnings (CARA)Research Analysts Set Expectations for Cara Therapeutics' Q2 2018 Earnings (CARA)
www.americanbankingnews.com - May 14 at 2:38 AM
Cara Therapeutics (CARA) Given a $22.00 Price Target by HC Wainwright AnalystsCara Therapeutics (CARA) Given a $22.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 11 at 8:04 PM
Cara Therapeutics (CARA) Releases  Earnings Results, Misses Expectations By $0.04 EPSCara Therapeutics (CARA) Releases Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 11 at 1:53 PM
Cara Therapeutics (CARA) CEO Derek Chalmers on Q1 2018 Results - Earnings Call TranscriptCara Therapeutics' (CARA) CEO Derek Chalmers on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:01 AM
Cara Therapeutics Reports First Quarter 2018 Financial ResultsCara Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 5:01 AM
Cara: 1Q Earnings SnapshotCara: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:01 AM
Cara Therapeutics to Announce First Quarter 2018 Financial Results on May 9, 2018Cara Therapeutics to Announce First Quarter 2018 Financial Results on May 9, 2018
finance.yahoo.com - May 3 at 5:13 AM
Edited Transcript of CARA earnings conference call or presentation 4-May-17 8:30pm GMTEdited Transcript of CARA earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 1 at 3:02 PM
4/20: Marijuana, hemp legalization moves ahead in many states4/20: Marijuana, hemp legalization moves ahead in many states
finance.yahoo.com - April 22 at 3:02 PM
Cara Therapeutics (CARA) Stock Rating Lowered by VetrCara Therapeutics (CARA) Stock Rating Lowered by Vetr
www.americanbankingnews.com - April 20 at 5:18 PM
Vetr Upgrades Cara Therapeutics (CARA) to "Buy"Vetr Upgrades Cara Therapeutics (CARA) to "Buy"
www.americanbankingnews.com - April 20 at 11:19 AM
Vetr Upgrades Cara Therapeutics (CARA) to "Strong-Buy"Vetr Upgrades Cara Therapeutics (CARA) to "Strong-Buy"
www.americanbankingnews.com - April 20 at 10:45 AM
Cara Therapeutics (CARA) Given Consensus Recommendation of "Buy" by BrokeragesCara Therapeutics (CARA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 19 at 5:55 AM
Cara Therapeutics (CARA) Downgraded by BidaskClubCara Therapeutics (CARA) Downgraded by BidaskClub
www.americanbankingnews.com - April 15 at 12:04 AM
Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney FoundationCara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation
finance.yahoo.com - April 10 at 3:01 PM
Needham & Company LLC Reiterates "Buy" Rating for Cara Therapeutics (CARA)Needham & Company LLC Reiterates "Buy" Rating for Cara Therapeutics (CARA)
www.americanbankingnews.com - April 7 at 11:00 PM
Heres Why Cara Therapeutics Slipped 11.4% in MarchHere's Why Cara Therapeutics Slipped 11.4% in March
www.msn.com - April 6 at 3:14 PM
Here's Why Cara Therapeutics Slipped 11.4% in MarchHere's Why Cara Therapeutics Slipped 11.4% in March
finance.yahoo.com - April 6 at 3:14 PM
Should You Be Concerned About Cara Therapeutics Inc’s (NASDAQ:CARA) Earnings Growth?Should You Be Concerned About Cara Therapeutics Inc’s (NASDAQ:CARA) Earnings Growth?
finance.yahoo.com - April 4 at 4:43 PM
Cara Therapeutics (CARA) Price Target Cut to $24.00 by Analysts at CIBCCara Therapeutics (CARA) Price Target Cut to $24.00 by Analysts at CIBC
www.americanbankingnews.com - April 1 at 2:38 PM
Cara Therapeutics (CARA) Price Target Raised to $26.00Cara Therapeutics (CARA) Price Target Raised to $26.00
www.americanbankingnews.com - April 1 at 2:38 PM
Cara Therapeutics (CARA) Rating Reiterated by BMO Capital MarketsCara Therapeutics (CARA) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - April 1 at 2:38 PM
Dont Get Greedy With Cara Therapeutics, Inc. StockDon't Get Greedy With Cara Therapeutics, Inc. Stock
www.msn.com - March 28 at 3:03 PM
Don't Get Greedy With Cara Therapeutics, Inc. StockDon't Get Greedy With Cara Therapeutics, Inc. Stock
finance.yahoo.com - March 28 at 3:03 PM
Cara Therapeutics Inc (CARA) Given Average Recommendation of "Buy" by AnalystsCara Therapeutics Inc (CARA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 25 at 5:36 AM
BidaskClub Downgrades Cara Therapeutics (CARA) to SellBidaskClub Downgrades Cara Therapeutics (CARA) to Sell
www.americanbankingnews.com - March 24 at 1:54 PM
Cara Therapeutics (CARA) "Buy" Rating Reaffirmed at Seaport Global SecuritiesCara Therapeutics' (CARA) "Buy" Rating Reaffirmed at Seaport Global Securities
www.americanbankingnews.com - March 22 at 8:12 PM
Zacks Investment Research Upgrades Cara Therapeutics (CARA) to HoldZacks Investment Research Upgrades Cara Therapeutics (CARA) to Hold
www.americanbankingnews.com - March 21 at 7:16 PM
Cramer's lightning round: With so many great bank stocks,...Cramer's lightning round: With so many great bank stocks,...
finance.yahoo.com - March 21 at 5:04 AM
Cramers lightning round: With so many great bank stocks, stay away from Wells FargoCramer's lightning round: With so many great bank stocks, stay away from Wells Fargo
finance.yahoo.com - March 21 at 5:04 AM
Cara Therapeutics (CARA) Given a $22.00 Price Target at HC WainwrightCara Therapeutics (CARA) Given a $22.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 19 at 5:02 PM
3 High-Risk, High-Reward Marijuana Stocks3 High-Risk, High-Reward Marijuana Stocks
finance.yahoo.com - March 19 at 3:04 PM
Cara Therapeutics Inc (NASDAQ:CARA): When Will It Breakeven?Cara Therapeutics Inc (NASDAQ:CARA): When Will It Breakeven?
finance.yahoo.com - March 16 at 3:02 PM
Edited Transcript of CARA earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of CARA earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 3:02 PM
Cara Therapeutics (CARA) Posts  Earnings Results, Misses Expectations By $0.04 EPSCara Therapeutics (CARA) Posts Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - March 16 at 9:28 AM
Cara Therapeutics Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)Cara Therapeutics Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 5:02 AM
Cara Therapeutics (CARA) CEO Derek Chalmers on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaCara Therapeutics' (CARA) CEO Derek Chalmers on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 5:02 AM
After-Hours Earnings Report for March 15, 2018 : ADBE, AVGO, ULTA, JBL, OSTK, REV, REI, FSM, GDEN, CBAY ... - NasdaqAfter-Hours Earnings Report for March 15, 2018 : ADBE, AVGO, ULTA, JBL, OSTK, REV, REI, FSM, GDEN, CBAY ... - Nasdaq
www.nasdaq.com - March 15 at 3:13 PM
Form 4 Cara Therapeutics, Inc. For: Mar 09 Filed by: Terrillion Scott - StreetInsider.comForm 4 Cara Therapeutics, Inc. For: Mar 09 Filed by: Terrillion Scott - StreetInsider.com
www.streetinsider.com - March 14 at 3:11 PM
Premarket analyst action - healthcare - Cara Therapeutics Inc ... - Seeking AlphaPremarket analyst action - healthcare - Cara Therapeutics Inc ... - Seeking Alpha
seekingalpha.com - March 13 at 5:08 AM
Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 - GlobeNewswire (press release)Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 - GlobeNewswire (press release)
globenewswire.com - March 9 at 5:07 AM
Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
finance.yahoo.com - March 9 at 5:07 AM
Enteris BioPharmas "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of ... - PR Newswire (press release)Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of ... - PR Newswire (press release)
www.prnewswire.com - March 1 at 3:03 PM

SEC Filings

Cara Therapeutics (NASDAQ:CARA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cara Therapeutics (NASDAQ:CARA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cara Therapeutics (NASDAQ CARA) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.